Discovery & Development

Industry experts share how their therapeutic products are shaping the future of the pharmaceutical landscape.

Is the regulator environment changing fast enough to accommodate the vast array of microbiome-based therapeutics beginning to emerge?

Looking for an experienced partner to simplify the development and manufacture of a new antibody-drug conjugate (ADC)?

Some have dismissed excitement about the microbiome as “hype,” but real results are beginning to be seen.

David Donabedian of Axial Biotherapuetics explains the role of the microbiome in the onset of Parkinson's Disease and autism.

It's time to rewrite the narrative about Africa's role in the pharmaceutical industry.

Oncology research has come a long way over the past 30 years, but we must transform outdated practices to further improve drug discovery innovation.

How is the changing landscape of microbiome R&D shaping conversations with regulators?

Researchers at the University of Bath have developed a technique which could prevent drugs from spoiling.

Male animal bias in preclinical research isn’t scientifically justified and may be skewing our understanding of the brain.